AU2015342895A1 - Use of compositions modulating chromatin structure for graft versus host disease (GVHD) - Google Patents

Use of compositions modulating chromatin structure for graft versus host disease (GVHD) Download PDF

Info

Publication number
AU2015342895A1
AU2015342895A1 AU2015342895A AU2015342895A AU2015342895A1 AU 2015342895 A1 AU2015342895 A1 AU 2015342895A1 AU 2015342895 A AU2015342895 A AU 2015342895A AU 2015342895 A AU2015342895 A AU 2015342895A AU 2015342895 A1 AU2015342895 A1 AU 2015342895A1
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
certain embodiments
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015342895A
Other languages
English (en)
Inventor
Bruce Blazar
James E. Bradner
Ryan Flynn
Jun Qi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
University of Minnesota System
Original Assignee
Dana Farber Cancer Institute Inc
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, University of Minnesota Twin Cities, University of Minnesota System filed Critical Dana Farber Cancer Institute Inc
Publication of AU2015342895A1 publication Critical patent/AU2015342895A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015342895A 2014-11-06 2015-11-06 Use of compositions modulating chromatin structure for graft versus host disease (GVHD) Abandoned AU2015342895A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076358P 2014-11-06 2014-11-06
US62/076,358 2014-11-06
PCT/US2015/059551 WO2016073903A1 (en) 2014-11-06 2015-11-06 Use of compositions modulating chromatin structure for graft versus host disease (gvhd)

Publications (1)

Publication Number Publication Date
AU2015342895A1 true AU2015342895A1 (en) 2017-05-18

Family

ID=55909890

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015342895A Abandoned AU2015342895A1 (en) 2014-11-06 2015-11-06 Use of compositions modulating chromatin structure for graft versus host disease (GVHD)

Country Status (9)

Country Link
US (1) US20190000860A1 (https=)
EP (1) EP3215160A4 (https=)
JP (1) JP2017533922A (https=)
KR (1) KR20170098808A (https=)
CN (1) CN107249593A (https=)
AU (1) AU2015342895A1 (https=)
BR (1) BR112017009440A2 (https=)
CA (1) CA2966336A1 (https=)
WO (1) WO2016073903A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016029492A2 (pt) 2014-06-17 2017-10-17 Eisai R&D Man Co Ltd método para tratamento de linfoma não hodgkin
EP3885343A1 (en) 2014-11-06 2021-09-29 Dana-Farber Cancer Institute, Inc. Indole compounds as ezh2 inhibitors and uses thereof
AU2016275051A1 (en) 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
AU2017252460B2 (en) 2016-04-22 2021-11-18 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
JP7125353B2 (ja) 2017-01-19 2022-08-24 第一三共株式会社 Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
CN108685880A (zh) * 2018-04-16 2018-10-23 广东省人民医院(广东省医学科学院) Bcl-6小分子抑制剂用于制备预防或治疗cGVHD的药物
CA3104209A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
JP2022514353A (ja) * 2018-12-21 2022-02-10 ザ ウォルター アンド イライザ ホール インスティテュート オブ メディカル リサーチ 炎症の治療方法
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
US12252493B2 (en) 2019-06-05 2025-03-18 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
CN112341390B (zh) * 2019-08-07 2022-08-23 四川大学 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
IL317937A (en) * 2022-08-09 2025-02-01 Dana Farber Cancer Inst Inc Macrocyclic BCL6 joints
WO2024211684A1 (en) * 2023-04-06 2024-10-10 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552083B1 (en) * 1999-07-16 2003-04-22 Kissei Pharmaceutical Co., Ltd. Agents inhibiting chronic rejection reactions after organ transplantation
US8338464B2 (en) * 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
KR20080107050A (ko) * 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
JP5889875B2 (ja) * 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アザインダゾール
US20120014979A1 (en) * 2010-07-16 2012-01-19 Alexander Dent Use of bcl6 inhibitors for treating autoimmune diseases
ES2951688T3 (es) * 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
EP2755962B1 (en) * 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
BR112014010803A2 (pt) * 2011-11-04 2017-04-25 Glaxosmithkline Intellectual Property (No 2) Ltd método de tratamento
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
US20130280332A1 (en) * 2012-02-17 2013-10-24 Nexbio, Inc. Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
WO2014155301A1 (en) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2

Also Published As

Publication number Publication date
CA2966336A1 (en) 2016-05-12
JP2017533922A (ja) 2017-11-16
EP3215160A4 (en) 2018-08-08
WO2016073903A1 (en) 2016-05-12
CN107249593A (zh) 2017-10-13
KR20170098808A (ko) 2017-08-30
BR112017009440A2 (pt) 2017-12-19
US20190000860A1 (en) 2019-01-03
EP3215160A1 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
AU2015342895A1 (en) Use of compositions modulating chromatin structure for graft versus host disease (GVHD)
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
JP6491202B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
CA3069181A1 (en) Compounds for tau protein degradation
WO2018085247A1 (en) Compounds for malt1 degradation
WO2017139414A1 (en) Inhibitor of indoleamine-2,3-dioxygenase (ido)
EP3688021A1 (en) Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
WO2018165385A1 (en) Inhibitors of malt1 and uses thereof
CA3019182A1 (en) Hck as a therapeutic target in myd88 mutated diseases
WO2021222542A1 (en) 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders
US20170233405A1 (en) Max binders as myc modulators and uses thereof
JP2023082101A (ja) 置換グリシン化合物の共結晶およびそれの使用
WO2024233839A1 (en) Small molecule inhibitors of glutaminase
CN113226468A (zh) 作为hcn1拮抗剂的经取代的烷基苯酚
AU2019318046A1 (en) Histone demethylase 5 inhibitors and uses thereof
EP3947382B1 (en) Compounds for uses in pharmacological induction of hbf for treatment of sickle cell disease and beta-thalassemia
CA3101561A1 (en) Combined therapy with icos binding proteins and argininemethyltransferase inhibitors
WO2026006669A1 (en) Prodrugs of n-[4-(6-fluoro-3,4-dihydro-2(1 h)-isoquinolinyl)-2,6-dimethylphe nyl]-3,3-dimethyl- butanamide
WO2025193275A2 (en) Compounds for inducing biostasis
WO2026039516A1 (en) Glucosylceramide synthase inhibitors and uses thereof
WO2024173766A1 (en) Cyclin dependent kinase degraders and methods of use thereof
WO2025090919A1 (en) Compositions and methods for treating inflammatory bowel disease
WO2022256480A1 (en) Arylcoumarin synthesis with azeotropic removal of water
WO2025038933A1 (en) Aryl amine compounds and uses thereof
KR20250129803A (ko) Pparg 조정제

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period